Interim data analysis of four-year, open-label extension from Phase 2/3 clinical trial suggests arimoclomol may reduce long-term progression of Niemann-Pick Disease Type C (NPC)
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/17/2022 | $20.00 | Overweight | Cantor Fitzgerald |
| 9/15/2022 | $20.00 | Buy | Canaccord Genuity |
| 1/31/2022 | $10.00 → $11.00 | Neutral → Buy | HC Wainwright & Co. |
CELEBRATION, Fla., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:KMPH) (Zevra, or the Company, formerly KemPharm, Inc.), a rare disease therapeutics company, has announced that the Company will host a conference call and live audio webcast on Tuesday, March 7, 2023, at 8:30 a.m. ET, to discuss its corporate and financial results for the fourth quarter and full-year 2022. The audio webcast with a slide presentation will be accessible via the Investor Relations section of the Company's website, http://investors.zevra.com/. An archive of the webcast and presentation will be available for 90 days beginning at approximately 9:30 a.m. ET, on March 7, 2023. Additionally, in
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today, November 9, 2022, at 5:00 p.m. ET Significant activities underway for preparation of the arimoclomol NDA resubmissionAdvancing key activities to initiate a Phase 2 clinical trial of KP1077 in IH by year-end 2022Total cash (cash, cash equivalents and long-term investments) of $107.4M as of Sep 30, 2022; based on current operating forecast, cash runway extends into 2026 CELEBRATION, Fla., Nov. 09, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH) (KemPharm, or the Company), a biotechnology company focused on the discovery, development and commercialization of novel treatments for rare central ne
CELEBRATION, Fla., Nov. 01, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH) (KemPharm, or the Company), a biotechnology company focused on the discovery, development and commercialization of novel treatments for rare diseases, today announced that the Company will host a conference call and live audio webcast on Wednesday, November 9, 2022, at 5:00 p.m. ET, to discuss its corporate and financial results for the third quarter 2022. The audio webcast with slide presentation will be accessible via the Investor Relations section of the Company's website, http://investors.kempharm.com/. An archive of the webcast and presentation will be available for 90 days beginning at approximately 6:
Matthew R. Plooster named Chairman of the Board of DirectorsRichard W. Pascoe appointed Chief Executive OfficerTravis C. Mickle, Ph.D. transitions to PresidentJoshua Schafer appointed Chief Commercial Officer and Executive Vice President of Business Development CELEBRATION, Fla., Jan. 09, 2023 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH) (KemPharm, or the Company), a rare disease therapeutics company focused on the development of treatments for rare central nervous system (CNS), neurodegenerative diseases, lysosomal storage disorders and related treatment areas, today announced changes to its Board of Directors (Board) and executive leadership team as part of the Company's ongoing b
24-year global pharmaceutical executive and current president and CEO of Cara Therapeutics joins KemPharm's Board of Directors CELEBRATION, Fla., Nov. 29, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH) (KemPharm, or the Company), a biotechnology company focused on the discovery, development and commercialization of novel treatments for rare central nervous system (CNS) and neurodegenerative diseases, lysosomal storage disorders and related treatment areas, today announced the appointment of Christopher Posner to serve on the Company's Board of Directors. Mr. Posner is currently the president and CEO of Cara Therapeutics (NASDAQ:CARA), a commercial-stage biopharmaceutical company.
CELEBRATION, Fla., Aug. 09, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH) (KemPharm, or the Company), a specialty pharmaceutical company focused on the discovery, development and commercialization of novel treatments for rare central nervous system (CNS), neurodegenerative and lysosomal storage diseases, today announced the appointment of Nichol Ochsner to the role of Vice President, Investor Relations and Corporate Communications. In this newly created position, Ms. Ochsner will be responsible for driving external awareness of KemPharm's value proposition, including ongoing relations with the Company's shareholders, covering analysts and prospective investors. "We are very plea
Cantor Fitzgerald initiated coverage of KemPharm with a rating of Overweight and set a new price target of $20.00
Canaccord Genuity initiated coverage of KemPharm with a rating of Buy and set a new price target of $20.00
HC Wainwright & Co. upgraded KemPharm from Neutral to Buy and set a new price target of $11.00 from $10.00 previously
SC 13G - ZEVRA THERAPEUTICS, INC. (0001434647) (Subject)
SC 13G - ZEVRA THERAPEUTICS, INC. (0001434647) (Subject)
SC 13G - KEMPHARM, INC (0001434647) (Subject)
4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)
4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)
4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)
S-3 - ZEVRA THERAPEUTICS, INC. (0001434647) (Filer)
8-K - ZEVRA THERAPEUTICS, INC. (0001434647) (Filer)
8-K - ZEVRA THERAPEUTICS, INC. (0001434647) (Filer)
Company's common stock will begin trading on the Nasdaq Global Select Market under the new ticker symbol "ZVRA" starting today, March 1, 2023 New Company name, Zevra, is Greek for zebra, the internationally recognized symbol for the rare disease community CELEBRATION, Fla., March 01, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics (NASDAQ:ZVRA) ("Zevra" or the "Company" and formerly KemPharm, Inc.), a rare disease therapeutics company, announced today that it will begin trading under the new ticker symbol "ZVRA" on the Nasdaq Global Select Market at market open today, March 1, 2023. The Company's new corporate name, along with the corresponding ticker symbol, embody Zevra's unwa
CELEBRATION, Fla., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:KMPH) ("Zevra" or the "Company" and formerly KemPharm, Inc.), a rare disease therapeutics company, today announced that it has become a Corporate Council member of the National Organization for Rare Disorders (NORD) and reiterated its commitment to the rare disease community by celebrating Rare Disease Day 2023. A rare disease is a condition that impacts fewer than 200,000 people in the United States, with over 7,000 known rare diseases nationally affecting nearly 1 in 10 people. NORD is dedicated to promoting research and access to therapies for the more than 300 million people worldwide with rare disea
CELEBRATION, Fla., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:KMPH) ("Zevra" or the "Company" and formerly known as KemPharm, Inc.), today announced it has filed its preliminary proxy statement with the U.S. Securities and Exchange Commission (the "SEC") in connection with the Company's 2023 Annual Meeting of Stockholders ("Annual Meeting"), which is scheduled to take place on April 25, 2023. Stockholders do not need to take any action with respect to the 2023 Annual Meeting at this time. In its preliminary proxy statement, Zevra announced that the Board has nominated three directors for re-election at the Company's Annual Meeting — Richard W. Pascoe, David S. Tier
Company's common stock will begin trading on the Nasdaq Global Select Market under the new ticker symbol "ZVRA" starting today, March 1, 2023 New Company name, Zevra, is Greek for zebra, the internationally recognized symbol for the rare disease community CELEBRATION, Fla., March 01, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics (NASDAQ:ZVRA) ("Zevra" or the "Company" and formerly KemPharm, Inc.), a rare disease therapeutics company, announced today that it will begin trading under the new ticker symbol "ZVRA" on the Nasdaq Global Select Market at market open today, March 1, 2023. The Company's new corporate name, along with the corresponding ticker symbol, embody Zevra's unwavering commi
Interim data analysis of four-year, open-label extension from Phase 2/3 clinical trial suggests arimoclomol may reduce long-term progression of Niemann-Pick Disease Type C (NPC)